


SURGLASSES Scaling Up: A research grant supports AR Surgical Glasses into huge Hospital Groups in Taiwan

SURGLASSES Scaling Up: A research grant supports AR Surgical Glasses into huge Hospital Groups in Taiwan

TAICHUNG CITY, TAIWAN, April 6, 2021 /EINPresswire.com/ -- Taiwan Main Orthopaedic Biotechnology Co. Ltd (<u>SURGLASSES</u>), a leading medical technology innovation company based in Taiwan. SURGLASSES recently received a 15-month grant from the Ministry of Science and Technology in Taiwan. SURGLASSES is co-operating with one of the biggest hospitals named Hualien Tzu Chi Hospital and focus on both virtual anatomy software development and <u>AR</u> medical solutions.

We appreciative the grant and would like to have a extensive co-operation with the Tzu Chi hospital. The goal is to create the full-body cadaver's experience including real human anatomy, pathology and the key steps of pre- surgical planning. Moreover, SURGLASSES will do the clinical trials of AR smart surgical glasses solutions into the Tzu Chi group hospitals to create a better eco-system in hospitals



altogether. SURGLASSES is very happy to announce the incoming valuable works with the leading hospitals. The AR surgical glasses will demonstrate the usage of the AR and <u>3D</u> <u>Navigation</u> beneficial not only the surgeons but also for the patients. Mr. ANURAG LAL (VISHU) Taiwan Main Orthopaedic Biotechnology Co. Ltd. Taiwan +886 906 788 825 tbk.sales@surglasses.com Visit us on social media: Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/538088922

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2021 IPD Group, Inc. All Right Reserved.